Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

Artur Jurczyszyn; Jorge J Castillo; Irit Avivi; Jacek Czepiel; Julio Davila; Ravi Vij; Mark A Fiala; Alessandro Gozzetti; Norbert Grząśko; Vibor Milunovic; Iwona Hus; Krzysztof Mądry; Anna Waszczuk-Gajda; Lidia Usnarska-Zubkiewicz; Jakub Dębski; Erden Atilla; Meral Beksac; Giuseppe Mele; Waldemar Sawicki; David Jayabalan; Grzegorz Charliński; Agoston Gyula Szabo; Roman Hajek; Michel Delforge; Agnieszka Kopacz; Dorotea Fantl; Anders Waage; Edvan Crusoe; Vania Hungria; Paul Richardson; Jacob Laubach; Thomas Guerrero-Garcia; Jieqi Liu; David H Vesole

doi:10.1080/10428194.2018.1473574

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

Artur Jurczyszyn, Jorge J Castillo, Irit Avivi, Jacek Czepiel, Julio Davila, Ravi Vij, Mark A Fiala, Alessandro Gozzetti, Norbert Grząśko, Vibor Milunovic, Iwona Hus, Krzysztof Mądry, Anna Waszczuk-Gajda, Lidia Usnarska-Zubkiewicz, Jakub Dębski, Erden Atilla, Meral Beksac, Giuseppe Mele, Waldemar Sawicki, David JayabalanGrzegorz Charliński, Agoston Gyula Szabo, Roman Hajek, Michel Delforge, Agnieszka Kopacz, Dorotea Fantl, Anders Waage, Edvan Crusoe, Vania Hungria, Paul Richardson, Jacob Laubach, Thomas Guerrero-Garcia, Jieqi Liu, David H Vesole

Haematology (Vejle)

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 109/L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p = .0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens.

Original language	English
Journal	Leukemia and Lymphoma
Volume	60
Issue number	1
Pages (from-to)	118-123
ISSN	1042-8194
DOIs	https://doi.org/10.1080/10428194.2018.1473574
Publication status	Published - Jan 2019

Keywords

Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
Humans
Immunologic Factors/therapeutic use
Leukemia, Plasma Cell/etiology
Male
Middle Aged
Multiple Myeloma/complications
Proteasome Inhibitors/therapeutic use
Retrospective Studies
Salvage Therapy/methods
Stem Cell Transplantation
Survival Analysis
Transplantation, Autologous
Treatment Outcome

Documents & Links

10.1080/10428194.2018.1473574

Cite this

Jurczyszyn, A., Castillo, J. J., Avivi, I., Czepiel, J., Davila, J., Vij, R., Fiala, M. A., Gozzetti, A., Grząśko, N., Milunovic, V., Hus, I., Mądry, K., Waszczuk-Gajda, A., Usnarska-Zubkiewicz, L., Dębski, J., Atilla, E., Beksac, M., Mele, G., Sawicki, W., ... Vesole, D. H. (2019). Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leukemia and Lymphoma, 60(1), 118-123. https://doi.org/10.1080/10428194.2018.1473574

Jurczyszyn, Artur ; Castillo, Jorge J ; Avivi, Irit ; Czepiel, Jacek ; Davila, Julio ; Vij, Ravi ; Fiala, Mark A ; Gozzetti, Alessandro ; Grząśko, Norbert ; Milunovic, Vibor ; Hus, Iwona ; Mądry, Krzysztof ; Waszczuk-Gajda, Anna ; Usnarska-Zubkiewicz, Lidia ; Dębski, Jakub ; Atilla, Erden ; Beksac, Meral ; Mele, Giuseppe ; Sawicki, Waldemar ; Jayabalan, David ; Charliński, Grzegorz ; Gyula Szabo, Agoston ; Hajek, Roman ; Delforge, Michel ; Kopacz, Agnieszka ; Fantl, Dorotea ; Waage, Anders ; Crusoe, Edvan ; Hungria, Vania ; Richardson, Paul ; Laubach, Jacob ; Guerrero-Garcia, Thomas ; Liu, Jieqi ; Vesole, David H. / Secondary plasma cell leukemia : a multicenter retrospective study of 101 patients. In: Leukemia and Lymphoma. 2019 ; Vol. 60, No. 1. pp. 118-123.

@article{7ed22b9ceb304869b95eb79dc899e15b,

title = "Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients",

abstract = "This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 109/L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p = .0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens.",

keywords = "Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Immunologic Factors/therapeutic use, Leukemia, Plasma Cell/etiology, Male, Middle Aged, Multiple Myeloma/complications, Proteasome Inhibitors/therapeutic use, Retrospective Studies, Salvage Therapy/methods, Stem Cell Transplantation, Survival Analysis, Transplantation, Autologous, Treatment Outcome",

author = "Artur Jurczyszyn and Castillo, {Jorge J} and Irit Avivi and Jacek Czepiel and Julio Davila and Ravi Vij and Fiala, {Mark A} and Alessandro Gozzetti and Norbert Grz{\c a}{\'s}ko and Vibor Milunovic and Iwona Hus and Krzysztof M{\c a}dry and Anna Waszczuk-Gajda and Lidia Usnarska-Zubkiewicz and Jakub D{\c e}bski and Erden Atilla and Meral Beksac and Giuseppe Mele and Waldemar Sawicki and David Jayabalan and Grzegorz Charli{\'n}ski and {Gyula Szabo}, Agoston and Roman Hajek and Michel Delforge and Agnieszka Kopacz and Dorotea Fantl and Anders Waage and Edvan Crusoe and Vania Hungria and Paul Richardson and Jacob Laubach and Thomas Guerrero-Garcia and Jieqi Liu and Vesole, {David H}",

year = "2019",

month = jan,

doi = "10.1080/10428194.2018.1473574",

language = "English",

volume = "60",

pages = "118--123",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor & Francis",

number = "1",

}

Jurczyszyn, A, Castillo, JJ, Avivi, I, Czepiel, J, Davila, J, Vij, R, Fiala, MA, Gozzetti, A, Grząśko, N, Milunovic, V, Hus, I, Mądry, K, Waszczuk-Gajda, A, Usnarska-Zubkiewicz, L, Dębski, J, Atilla, E, Beksac, M, Mele, G, Sawicki, W, Jayabalan, D, Charliński, G, Gyula Szabo, A, Hajek, R, Delforge, M, Kopacz, A, Fantl, D, Waage, A, Crusoe, E, Hungria, V, Richardson, P, Laubach, J, Guerrero-Garcia, T, Liu, J & Vesole, DH 2019, 'Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients', Leukemia and Lymphoma, vol. 60, no. 1, pp. 118-123. https://doi.org/10.1080/10428194.2018.1473574

Secondary plasma cell leukemia : a multicenter retrospective study of 101 patients. / Jurczyszyn, Artur; Castillo, Jorge J; Avivi, Irit; Czepiel, Jacek; Davila, Julio; Vij, Ravi; Fiala, Mark A; Gozzetti, Alessandro; Grząśko, Norbert; Milunovic, Vibor; Hus, Iwona; Mądry, Krzysztof; Waszczuk-Gajda, Anna; Usnarska-Zubkiewicz, Lidia; Dębski, Jakub; Atilla, Erden; Beksac, Meral; Mele, Giuseppe; Sawicki, Waldemar; Jayabalan, David; Charliński, Grzegorz; Gyula Szabo, Agoston; Hajek, Roman; Delforge, Michel; Kopacz, Agnieszka; Fantl, Dorotea; Waage, Anders; Crusoe, Edvan; Hungria, Vania; Richardson, Paul; Laubach, Jacob; Guerrero-Garcia, Thomas; Liu, Jieqi; Vesole, David H.

In: Leukemia and Lymphoma, Vol. 60, No. 1, 01.2019, p. 118-123.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Secondary plasma cell leukemia

T2 - a multicenter retrospective study of 101 patients

AU - Jurczyszyn, Artur

AU - Castillo, Jorge J

AU - Avivi, Irit

AU - Czepiel, Jacek

AU - Davila, Julio

AU - Vij, Ravi

AU - Fiala, Mark A

AU - Gozzetti, Alessandro

AU - Grząśko, Norbert

AU - Milunovic, Vibor

AU - Hus, Iwona

AU - Mądry, Krzysztof

AU - Waszczuk-Gajda, Anna

AU - Usnarska-Zubkiewicz, Lidia

AU - Dębski, Jakub

AU - Atilla, Erden

AU - Beksac, Meral

AU - Mele, Giuseppe

AU - Sawicki, Waldemar

AU - Jayabalan, David

AU - Charliński, Grzegorz

AU - Gyula Szabo, Agoston

AU - Hajek, Roman

AU - Delforge, Michel

AU - Kopacz, Agnieszka

AU - Fantl, Dorotea

AU - Waage, Anders

AU - Crusoe, Edvan

AU - Hungria, Vania

AU - Richardson, Paul

AU - Laubach, Jacob

AU - Guerrero-Garcia, Thomas

AU - Liu, Jieqi

AU - Vesole, David H

PY - 2019/1

Y1 - 2019/1

N2 - This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 109/L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p = .0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens.

AB - This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 109/L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p = .0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Immunologic Factors/therapeutic use

KW - Leukemia, Plasma Cell/etiology

KW - Male

KW - Middle Aged

KW - Multiple Myeloma/complications

KW - Proteasome Inhibitors/therapeutic use

KW - Retrospective Studies

KW - Salvage Therapy/methods

KW - Stem Cell Transplantation

KW - Survival Analysis

KW - Transplantation, Autologous

KW - Treatment Outcome

U2 - 10.1080/10428194.2018.1473574

DO - 10.1080/10428194.2018.1473574

M3 - Journal article

C2 - 29965787

VL - 60

SP - 118

EP - 123

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

Abstract

Keywords

Documents & Links

Fingerprint

Cite this